Tango Therapeutics annual return on equity
2021
2022
2023
2024
2025
Tango Therapeutics Return on Equity (ROE) Growth & History (TNGX)
Tango Therapeutics's return on equity was −37.23% for fiscal 2025.
View full Tango Therapeutics company overviewTango Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −37.23% | +20.34 pp |
| 2024 | 2024-12-31 | −57.58% | −17.09 pp |
| 2023 | 2023-12-31 | −40.49% | −4.08 pp |
| 2022 | 2022-12-31 | −36.41% | −6.03 pp |
| 2021 | 2021-12-31 | −30.38% | — |
Tango Therapeutics quarterly return on equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.82% | +17.94 pp |
| Q1 2026 | 2026-03-31 | −12.34% | +9.43 pp |
| Q4 2025 | 2025-12-31 | −15.31% | +2.27 pp |
| Q3 2025 | 2025-09-30 | 10.77% | +23.00 pp |
| Q2 2025 | 2025-06-30 | −25.76% | −15.78 pp |
| Q1 2025 | 2025-03-31 | −21.77% | −7.12 pp |
| Q4 2024 | 2024-12-31 | −17.57% | −5.96 pp |
| Q3 2024 | 2024-09-30 | −12.23% | −3.14 pp |
| Q2 2024 | 2024-06-30 | −9.98% | −0.57 pp |
| Q1 2024 | 2024-03-31 | −14.65% | −2.90 pp |
| Q4 2023 | 2023-12-31 | −11.62% | −0.49 pp |
| Q3 2023 | 2023-09-30 | −9.10% | +1.07 pp |
| Q2 2023 | 2023-06-30 | −9.41% | −1.38 pp |
| Q1 2023 | 2023-03-31 | −11.75% | −4.17 pp |
| Q4 2022 | 2022-12-31 | −11.12% | −4.91 pp |
| Q3 2022 | 2022-09-30 | −10.16% | −0.84 pp |
| Q2 2022 | 2022-06-30 | −8.03% | −0.06 pp |
| Q1 2022 | 2022-03-31 | −7.58% | +17.51 pp |
| Q4 2021 | 2021-12-31 | −6.21% | +14.52 pp |
| Q3 2021 | 2021-09-30 | −9.32% | — |
| Q2 2021 | 2021-06-30 | −7.97% | — |
| Q1 2021 | 2021-03-31 | −25.09% | — |
| Q4 2020 | 2020-12-31 | −20.73% | — |
Tango Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Tango Therapeutics's return on equity decreased from −30.38% to −37.23%, a change of −6.85 percentage points. The latest reported quarter, Q2 2026, shows −7.82%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tango Therapeutics source filings ↗